SLC35A2 and breast carcinoma: Previous studies have reported that SLC35A2 participates in promoting the metastasis of hepatocellular carcinoma by regulating cell glycosylation, and it’s up-regulation is consistent with the enhanced metastatic ability of HCC cells and the poor prognosis of HCC patients, which may become a potential intervention target for the treatment of advanced HCC in the future [17]; In breast cancer tissues, SLC35A2 is significantly upregulated [18], possibly contributing to breast cancer inflammation and diagnosis [19].